Strides Pharma Science Limited

Strides Pharma Science Limited (STAR) is a small-cap Healthcare company valued at ₹9,624 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Strides Pharma Science Limited last traded at ₹1,062, down 2.10% on the day.

Recent developments

On 2026-07-31, the company reported a 56.7% rise in first-quarter PAT to ₹165.5 crore, with revenue at ₹1,265.4 crore, up from ₹1,119.7 crore a year earlier. On 2026-06-27, the company informed the exchange about the sale or disposal of a unit, division, or subsidiary. On the same day, the company announced a partnership with Ascent Capital to unlock value in its pivot path.

Financial performance

The company's annual revenue rose 6.4% to ₹4,859 crore, but net profit fell 84.0% to ₹575 crore. In the latest quarter, revenue grew 13.0% to ₹1,265 crore, while net profit surged 56.1% to ₹165 crore, showing improvement in profitability compared to the same quarter a year earlier.

Valuation multiples

The stock trades at 17.6 times earnings, a discount to the Healthcare median of 32.0, 3.61 times book value. It yields 0.4%.

Things to watch

The company's net profit margin dropped 67.0 percentage points to 11.8% from 78.8% in the prior year. Promoter shares pledged account for 38.10% of promoter holding, and the stock is 14.0% below its 52-week high.

Where it stands

The company's latest quarter showed a significant rise in net profit, but annual net profit fell sharply. The stock is 14.0% below its 52-week high, and the net profit margin has declined substantially.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.